Skip to search formSkip to main contentSkip to account menu

vardenafil

Known as: Vardenafilum, Vardénafil, 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-F][1,2,4]triazin-4(1H)-one 
A benzenesulfonamide derivative and phosphodiesterase type 5 (PDE5) inhibitor with vasodilatory activity. Vardenafil selectively inhibits PDE5, thus… 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

LevitraVardenafil hydrochlorideVardenafil hydrochloride trihydrate
NitratesNitroglycerinVardenafil:MCnc:Pt:Bld:QnVardenafil:MCnc:Pt:Ser/Plas:Qn

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Vardenafil, a clinically available phosphodiesterase inhibitor, potentiates the killing effect of EGCG on CLL cells
helped to conceptualize the structure of the study. YZ contributed to the execution of the research. VJ helped with data analysis… 
Review
2012
Review
2012
Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using tadalafil once-daily
Introduction: Tadalafil distinguishes itself from other available phosphodiesterase type 5 (PDE-5) inhibitors by its half-life of… 
2012
2012
Validation of an LC-ESI-MS/MS method for the quantitation of phosphodiesterase-5 inhibitors and their main metabolites in rat serum and brain tissue samples.
2011
2011
Identification of novel sildenafil-analogues in an adulterated herbal food supplement.
Review
2006
Review
2006
Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction.
2006
2006
Phosphodiesterase-5 Gln817 Is Critical for cGMP, Vardenafil, or Sildenafil Affinity
The side group of an invariant Gln in cGMP- and cAMP-specific phosphodiesterases (PDE) is held in different orientations by bonds… 
2006
2006
Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
2006
2006
Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil
Despite close structural similarity, vardenafil (Levitra®) is 32-fold more potent than sildenafil (Viagra®) to inhibit cGMP… 
Review
2005
Review
2005
Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Review
2005
Review
2005
Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)